Rachel Saunders-Pullman1,2, Roy N Alcalay3,4, Anat Mirelman5, Cuiling Wang6, Marta San Luciano7, Roberto A Ortega1, Amanda Glickman1, Deborah Raymond1, Helen Mejia-Santana3, Nancy Doan1, Brooke Johannes1, Kira Yasinovsky5, Laurie Ozelius2,8, Lorraine Clark4,9, Avi Orr-Utreger10, Karen Marder3,4,11,12, Nir Giladi5, Susan B Bressman1,2. 1. Department of Neurology, Mount Sinai Beth Israel Medical Center, New York, New York, USA. 2. Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 3. Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA. 4. Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, NY, USA. 5. Movement Disorders Unit, Department of Neurology, Tel-Aviv Medical Center, Sieratzki Chair of Neurology, Department of Neurology and Neurosurgery, Sackler School of Medicine, Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel. 6. Department of Epidemiology and Social Medicine, Albert Einstein College of Medicine, Bronx, New York, USA. 7. Department of Neurology, University of California San Francisco, San Francisco, California, USA. 8. Department of Genetics, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 9. Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, New York, USA. 10. Genetic Institute, Tel-Aviv Medical Center, Sackler School of Medicine, Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel. 11. Gertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, New York, USA. 12. Department of Psychiatry, Columbia University Medical Center, New York, New York, USA.
Abstract
BACKGROUND: Rapid eye movement sleep behavior disorder occurs with idiopathic Parkinson's disease (PD) and often precedes PD. Its frequency in LRRK2-PD and utility as a preclinical marker has not been established. METHODS: One hundred forty-four idiopathic PD, 142 LRRK2 G2019S mutation PD, 117 non-manifesting carriers, 93 related noncarriers, and 40 healthy controls completed the Rapid eye movement sleep Behavior Disorder Screening Questionnaire. RESULTS: Cut scores were met by 30.6% idiopathic PD, 19.7% LRRK2-PD, 6% nonmanifesting carriers, 20.4% related noncarriers, and 15% controls. The likelihood of abnormal scores was decreased in LRRK2-PD versus idiopathic PD (odds ratio = 0.55, P = 0.03), nonmanifesting carriers versus related noncarriers (OR = 0.25, P < 0.01), and PD of less than 3 years' duration, 1 of 19 LRRK2-PD versus 14 of 41 idiopathic PD (P < 0.05). CONCLUSIONS: A lower frequency of abnormal questionnaire scores is seen in LRRK2-PD, especially in early LRRK2-PD, and in nonmanifesting carriers. Therefore, the Rapid eye movement sleep Behavior Disorder Questionnaire is unlikely to serve as a preclinical marker for phenoconversion to PD.
BACKGROUND:Rapid eye movement sleep behavior disorder occurs with idiopathic Parkinson's disease (PD) and often precedes PD. Its frequency in LRRK2-PD and utility as a preclinical marker has not been established. METHODS: One hundred forty-four idiopathic PD, 142 LRRK2G2019S mutation PD, 117 non-manifesting carriers, 93 related noncarriers, and 40 healthy controls completed the Rapid eye movement sleep Behavior Disorder Screening Questionnaire. RESULTS: Cut scores were met by 30.6% idiopathic PD, 19.7% LRRK2-PD, 6% nonmanifesting carriers, 20.4% related noncarriers, and 15% controls. The likelihood of abnormal scores was decreased in LRRK2-PD versus idiopathic PD (odds ratio = 0.55, P = 0.03), nonmanifesting carriers versus related noncarriers (OR = 0.25, P < 0.01), and PD of less than 3 years' duration, 1 of 19 LRRK2-PD versus 14 of 41 idiopathic PD (P < 0.05). CONCLUSIONS: A lower frequency of abnormal questionnaire scores is seen in LRRK2-PD, especially in early LRRK2-PD, and in nonmanifesting carriers. Therefore, the Rapid eye movement sleep Behavior Disorder Questionnaire is unlikely to serve as a preclinical marker for phenoconversion to PD.
Authors: Ronald B Postuma; Dag Aarsland; Paolo Barone; David J Burn; Christopher H Hawkes; Wolfgang Oertel; Tjalf Ziemssen Journal: Mov Disord Date: 2012-04-15 Impact factor: 10.338
Authors: Alex Iranzo; Eduard Tolosa; Ellen Gelpi; José Luis Molinuevo; Francesc Valldeoriola; Mónica Serradell; Raquel Sanchez-Valle; Isabel Vilaseca; Francisco Lomeña; Dolores Vilas; Albert Lladó; Carles Gaig; Joan Santamaria Journal: Lancet Neurol Date: 2013-04-03 Impact factor: 44.182
Authors: Roy N Alcalay; Anat Mirelman; Rachel Saunders-Pullman; Ming-X Tang; Helen Mejia Santana; Deborah Raymond; Ernest Roos; Martha Orbe-Reilly; Tanya Gurevich; Anat Bar Shira; Mali Gana Weisz; Kira Yasinovsky; Maayan Zalis; Avner Thaler; Andres Deik; Matthew James Barrett; Jose Cabassa; Mark Groves; Ann L Hunt; Naomi Lubarr; Marta San Luciano; Joan Miravite; Christina Palmese; Rivka Sachdev; Harini Sarva; Lawrence Severt; Vicki Shanker; Matthew Carrington Swan; Jeannie Soto-Valencia; Brooke Johannes; Robert Ortega; Stanley Fahn; Lucien Cote; Cheryl Waters; Pietro Mazzoni; Blair Ford; Elan Louis; Oren Levy; Llency Rosado; Diana Ruiz; Tsvyatko Dorovski; Michael Pauciulo; William Nichols; Avi Orr-Urtreger; Laurie Ozelius; Lorraine Clark; Nir Giladi; Susan Bressman; Karen S Marder Journal: Mov Disord Date: 2013-10-15 Impact factor: 10.338
Authors: Rachel Saunders-Pullman; Anat Mirelman; Roy N Alcalay; Cuiling Wang; Roberto A Ortega; Deborah Raymond; Helen Mejia-Santana; Martha Orbe-Reilly; Brooke A Johannes; Avner Thaler; Laurie Ozelius; Avi Orr-Urtreger; Karen S Marder; Nir Giladi; Susan B Bressman Journal: JAMA Neurol Date: 2018-03-01 Impact factor: 18.302